Hypocholesterolemic and immunostimulatory effects of orally applied Enterococcus faecium M-74 in man
Language English Country United States Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
8768254
DOI
10.1007/bf02818522
Knihovny.cz E-resources
- MeSH
- Adjuvants, Immunologic administration & dosage therapeutic use MeSH
- Anticholesteremic Agents administration & dosage therapeutic use MeSH
- Administration, Oral MeSH
- Cholesterol blood MeSH
- Adult MeSH
- Enterococcus faecium * immunology physiology MeSH
- Immunoglobulin G biosynthesis MeSH
- Middle Aged MeSH
- Humans MeSH
- Lipoproteins, LDL blood MeSH
- Freeze Drying MeSH
- Neutrophils drug effects metabolism MeSH
- Oxidation-Reduction MeSH
- Respiratory Burst drug effects MeSH
- Aged MeSH
- Tetradecanoylphorbol Acetate pharmacology MeSH
- Antibody Formation drug effects MeSH
- Zymosan pharmacology MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Adjuvants, Immunologic MeSH
- Anticholesteremic Agents MeSH
- Cholesterol MeSH
- Immunoglobulin G MeSH
- Lipoproteins, LDL MeSH
- Tetradecanoylphorbol Acetate MeSH
- Zymosan MeSH
Lyophilized Enterococcus faecium M-74 was administered to 12 adult subjects in a daily oral dose of 5 x 10(9) bacteria for six weeks. The bacterium temporarily colonized the host intestine and its excretion with stool persisted for five weeks after the last does. The mean levels of serum cholesterol and LDL showed a a biphasic effect--an elevation followed by a sharp decrease (on day 64 of investigation). The decrease corresponded in time with a significant increase in the ability to reduce iodonitrotetrazolium and superoxide production by peripheral neutrophils incubated with zymosan or phorbol myristate acetate, and also with an elevated production of IgG by peripheral blood mononuclear cells. Hence, intake of E. faecium may have a hypocholesterolemic and immunostimulatory effect. It was also demonstrated that E. faecium significantly reduced the average activity of beta-D-glucuronidase in stools.
See more in PubMed
Biochim Biophys Acta. 1993 Aug 18;1178(2):221-7 PubMed
Immunol Lett. 1993 Dec;39(1):71-5 PubMed
Acta Pathol Jpn. 1989 Aug;39(8):473-86 PubMed
J Dairy Sci. 1984 Feb;67(2):255-62 PubMed
Atherosclerosis. 1977 Mar;26(3):335-40 PubMed
Biochemistry. 1994 Aug 23;33(33):10127-36 PubMed
FEMS Microbiol Rev. 1993 Sep;12(1-3):207-20 PubMed
J Pediatr Gastroenterol Nutr. 1990 Nov;11(4):509-12 PubMed
J Biol Chem. 1959 Jun;234(6):1355-62 PubMed
Biochem Biophys Res Commun. 1994 Aug 15;202(3):1300-7 PubMed
Agents Actions. 1982 Oct;12(4):478-84 PubMed
Dig Dis Sci. 1992 Jan;37(1):121-8 PubMed
Scand J Clin Lab Invest Suppl. 1968;97:77-89 PubMed
Biochem J. 1994 Aug 15;302 ( Pt 1):297-304 PubMed
Biochem J. 1994 Jul 15;301 ( Pt 2):421-8 PubMed
Am J Clin Nutr. 1984 May;39(5):756-61 PubMed
Trends Biochem Sci. 1993 Feb;18(2):43-7 PubMed
Annu Rev Biochem. 1983;52:223-61 PubMed
Bratisl Lek Listy. 1988 Jun;89(6):424-32 PubMed
Proc Natl Acad Sci U S A. 1984 Jun;81(12):3883-7 PubMed
Biochem J. 1993 Feb 15;290 ( Pt 1):165-72 PubMed
Int J Immunopharmacol. 1990;12(6):675-84 PubMed
Nature. 1993 Apr 29;362(6423):801-9 PubMed
Infect Immun. 1989 Nov;57(11):3576-80 PubMed
Biochem Biophys Res Commun. 1988 Feb 15;150(3):1294-301 PubMed
World J Microbiol Biotechnol. 1995 May;11(3):294-8 PubMed
FEMS Microbiol Rev. 1990 Sep;7(1-2):175-88 PubMed
Microbiologica. 1992 Oct;15(4):413-7 PubMed
J Dairy Sci. 1989 Nov;72(11):2885-99 PubMed
Beneficial health effects of milk and fermented dairy products--review
Antimutagenicity of milk fermented by Enterococcus faecium
